story of the week
Fulvestrant + Vistusertib vs Fulvestrant + Everolimus vs Fulvestrant Alone in HR+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
JAMA Oncol 2019 Aug 29;[EPub Ahead of Print], P Schmid, M Zaiss, C Harper-Wynne, M Ferreira, S Dubey, S Chan, A Makris, G Nemsadze, AM Brunt, S Kuemmel, I Ruiz, A Perelló, A Kendall, J Brown, H Kristeleit, J Conibear, C Saura, J Grenier, K Máhr, M Schenker, J Sohn, KS Lee, CJ Shepherd, E Oelmann, SJ Sarker, A Prendergast, P Marosics, A Moosa, C Lawrence, C Coetzee, K Mousa, J CortésFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.